Hepatic manifestations of inflammatory bowel diseases

被引:72
作者
Restellini, Sophie [1 ]
Chazouilleres, Olivier [2 ,3 ]
Frossard, Jean-Louis [1 ]
机构
[1] Univ Hosp Geneva, Serv Gastroenterol & Hepatol, Geneva, Switzerland
[2] Ctr Reference Malad Inflammatoires Voies Biliaire, Div Hepatol, Paris, France
[3] UPMC Univ Paris 06, Univ Sorbonne, Hop St Antoine, AP HP,UMR S 938,CDR St Antoine, Paris, France
关键词
drug-induced liver injury; hepatotoxicity; inflammatory bowel disease; liver disease; primary sclerosing cholangitis; PRIMARY SCLEROSING CHOLANGITIS; NODULAR REGENERATIVE HYPERPLASIA; FATTY LIVER-DISEASE; CHRONIC ULCERATIVE-COLITIS; PRIMARY BILIARY-CIRRHOSIS; POUCH-ANAL ANASTOMOSIS; B-VIRUS REACTIVATION; NATURAL-HISTORY; CROHNS-DISEASE; AUTOIMMUNE HEPATITIS;
D O I
10.1111/liv.13265
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Inflammatory bowel diseases are associated with various hepatobiliary disorders, reported both in Crohn's disease and ulcerative colitis. They may occur at any moment in the natural course of the disease. The prevalence of liver dysfunction rises from 3% to 50% accordingly to definitions used in different studies. Fatty liver is considered as the most common hepatobiliary complication in inflammatory bowel diseases while primary sclerosing cholangitis is the most specific one. Less frequently, inflammatory bowel diseases-associated hepatobiliary disorders include: autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome, IgG4-associated cholangiopathy, primary biliary cholangitis, hepatic amyloidosis, granulomatous hepatitis, cholelithiasis, portal vein thrombosis and liver abscess. The spectrum of these manifestations varies according to the type of inflammatory bowel diseases. Treatments of inflammatory bowel diseases may cause liver toxicity, although incidence of serious complications remains low. However, early diagnosis of drug-induced liver injury is of major importance as it affects future clinical management. When facing abnormal liver tests, clinicians should undertake a full diagnostic work-up in order to determine whether the hepatic abnormalities are related to the inflammatory bowel diseases or not. Management of hepatic manifestations in inflammatory bowel diseases usually involves both hepatologists and gastroenterologists because of the complexity of some situations.
引用
收藏
页码:475 / 489
页数:15
相关论文
共 151 条
  • [1] Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome
    Abdo, AA
    Bain, VG
    Kichian, K
    Lee, SS
    [J]. HEPATOLOGY, 2002, 36 (06) : 1393 - 1399
  • [2] Natalizumab-induced hepatic injury: A case report and review of literature
    Antezana, A.
    Sigal, S.
    Herbert, J.
    Kister, I.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (06) : 495 - 498
  • [3] Baddley JW, 1999, AM J GASTROENTEROL, V94, P847, DOI 10.1111/j.1572-0241.1999.00959.x
  • [4] CT depiction of portal vein thrombi after creation of ileal pouch-anal anastomosis
    Baker, ME
    Remzi, F
    Einstein, D
    Oncel, M
    Herts, B
    Remer, E
    Fazio, V
    [J]. RADIOLOGY, 2003, 227 (01) : 73 - 79
  • [5] Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community
    Bambha, K
    Kim, WR
    Talwalkar, J
    Torgerson, H
    Benson, JT
    Therneau, TM
    Loftus, EV
    Yawn, BP
    Dickson, ER
    Melton, LJ
    [J]. GASTROENTEROLOGY, 2003, 125 (05) : 1364 - 1369
  • [6] Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: Prevalence, titre, and IgG subclass
    Bansi, DS
    Fleming, KA
    Chapman, RW
    [J]. GUT, 1996, 38 (03) : 384 - 389
  • [7] Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial
    Barbero-Villares, A.
    Mendoza Jimenez-Ridruejo, J.
    Taxonera, C.
    Lopez-Sanroman, A.
    Pajares, R.
    Bermejo, F.
    Perez-Calle, J. L.
    Mendoza, J. L.
    Algaba, A.
    Moreno-Otero, R.
    Mate, J.
    Gisbert, J. P.
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (05) : 575 - 579
  • [8] Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet
    Barbuio, Raquel
    Milanski, Marciane
    Bertolo, Manoel B.
    Saad, Mario J.
    Velloso, Licio A.
    [J]. JOURNAL OF ENDOCRINOLOGY, 2007, 194 (03) : 539 - 550
  • [9] Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease
    Bastida, G
    Nos, P
    Aguas, M
    Beltrán, B
    Rubín, A
    Dasí, F
    Ponce, J
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (09) : 775 - 782
  • [10] Increased prevalence of primary sclerosing cholangitis among first-degree relatives
    Bergquist, A
    Lindberg, G
    Saarinen, S
    Broomé, U
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (02) : 252 - 256